Rivaroxaban (BioDeep_00000743409)
代谢物信息卡片
Rivaroxaban
化学式: C19H18ClN3O5S (435.06556480000006)
中文名称: 利伐沙班
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1COCC(=O)N1C2=CC=C(C=C2)N3CC(OC3=O)CNC(=O)C4=CC=C(S4)Cl
InChI: InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
描述信息
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AF - Direct factor xa inhibitors
C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C173067 - Direct Factor Xa Inhibitor
C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C180619 - Direct Oral Anticoagulant
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors
D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
1 个代谢物同义名
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:68579
- KEGGdrug: D07086
- PubChem: 9875401
- DrugBank: DB06228
- ChEMBL: CHEMBL198362
- MeSH: Rivaroxaban
- CAS: 1429742-50-6
- CAS: 366789-02-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Yanan Guo, Sisi Dong, Meng Li, Yanyan Tao, Jing Lv, Chenghai Liu. A new model of portal vein thrombosis in rats with cirrhosis induced by partial portal vein ligation plus carbon tetrachloride and intervened with rivaroxaban.
BMC gastroenterology.
2024 May; 24(1):161. doi:
10.1186/s12876-024-03253-4. [PMID: 38741060] - Yuan Lin, Tze-Fan Chao, Ming-Lung Tsai, Chin-Ju Tseng, Te-Hsiung Wang, Chih-Hsiang Chang, Yu-Sheng Lin, Ning-I Yang, Pao-Hsien Chu, Ming-Jui Hung, Victor Chien-Chia Wu, Tien-Hsing Chen. Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4-5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study.
Journal of thrombosis and thrombolysis.
2023 Aug; ?(?):. doi:
10.1007/s11239-023-02885-9. [PMID: 37605063] - Giuseppe Derosa, Manfredi Rizzo, Natale Daniele Brunetti, Riccardo Raddino, Mara Gavazzoni, Gianfranco Pasini, Giovanni Gaudio, Antonio Maggi, Angela D'Angelo, Luisa De Gennaro, Pamela Maffioli. ORal anticoaGulants in diAbetic and Nondiabetic patients with nOn-valvular atrial fibrillatioN (ORGANON).
Journal of diabetes and its complications.
2023 08; 37(8):108512. doi:
10.1016/j.jdiacomp.2023.108512. [PMID: 37390799] - Dandan Zheng, Gui Qi, Isaac Kumi Adu, Haichao Wu, Mingyuan Zhu. Efficacy of traditional Chinese medicine combined with rivaroxaban in the treatment of lower extremity deep vein thrombosis: A meta-analysis.
Medicine.
2022 Sep; 101(39):e29483. doi:
10.1097/md.0000000000029483. [PMID: 36181038] - Jean Terrier, Frédéric Gaspar, Monia Guidi, Pierre Fontana, Youssef Daali, Chantal Csajka, Jean-Luc Reny. Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation.
Clinical pharmacology and therapeutics.
2022 Aug; 112(2):353-363. doi:
10.1002/cpt.2649. [PMID: 35593020] - Rachel Aakerøy, Charlotte L Stokes, Marija Tomić, Solfrid Hegstad, Ann Helen Kristoffersen, Hanne Ellekjær, Jan Schjøtt, Olav Spigset, Arne Helland. Serum or Plasma for Quantification of Direct Oral Anticoagulants?.
Therapeutic drug monitoring.
2022 Aug; 44(4):578-584. doi:
10.1097/ftd.0000000000000956. [PMID: 35051972] - Luis Genis-Najera, Maria Elena Sañudo-Maury, Trinifer Moquete. A Single-blind, Randomized, Single-dose, Two-sequence, Two-period, Crossover Study to Assess the Bioequivalence between Two Oral Tablet Formulations of Rivaroxaban 20 mg in Healthy Mexican Volunteers.
Clinical pharmacology in drug development.
2022 Jul; 11(7):826-831. doi:
10.1002/cpdd.1092. [PMID: 35510948] - Takako Terakami, Satomi Nagaya, Kenshi Hayashi, Hiroshi Furusho, Noboru Fujino, Takeshi Kato, Hidesaku Asakura, Eriko Morishita. Effect on Plasma Protein S Activity in Patients Receiving the Factor Xa Inhibitors.
Journal of atherosclerosis and thrombosis.
2022 Jul; 29(7):1059-1068. doi:
10.5551/jat.62951. [PMID: 34334529] - Sajidah Alkhameys, Ravina Barrett. Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): an interrupted time series analysis (January 2019-February 2021).
Current medical research and opinion.
2022 Jul; 38(7):1081-1092. doi:
10.1080/03007995.2022.2078100. [PMID: 35582854] - Feilong Zhang, Xuehai Chen, Tingting Wu, Nianxu Huang, Li Li, Dongdong Yuan, Jing Xiang, Na Wang, Wenjun Chen, Jinhua Zhang. Population Pharmacokinetics of Rivaroxaban in Chinese Patients with Non-Valvular Atrial Fibrillation: A Prospective Multicenter Study.
Clinical pharmacokinetics.
2022 06; 61(6):881-893. doi:
10.1007/s40262-022-01108-3. [PMID: 35316848] - Francesco Negro, Paolo Caravelli, Riccardo Morganti, Monica Casini, Lucia Ruocco, Armando Tripodi, Raffaele De Caterina. The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time.
Vascular pharmacology.
2022 06; 144(?):106994. doi:
10.1016/j.vph.2022.106994. [PMID: 35436607] - Marion Gaudard, Elodie Boissier, Laurie Talon, Jonathan Douxfils, Anne-Françoise Sapin, Thomas Sinegre, Aurélien Lebreton. Stability of coagulation parameters in plasma samples at room temperature after one freeze/thaw cycle.
International journal of laboratory hematology.
2022 Jun; 44(3):610-618. doi:
10.1111/ijlh.13794. [PMID: 35029031] - Darius Kl Aw, Edward Tc Choke. Superior Mesenteric Artery Thrombosis While on Rivaroxaban in a Patient With COVID-19.
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
2022 Jun; 63(6):889. doi:
10.1016/j.ejvs.2022.03.016. [PMID: 35589486] - Maxime Delrue, Lucie Chevillard, Alain Stépanian, Alessandra Dragoni, Laurence Camoin-Jau, Sébastien Voicu, Isabelle Malissin, Nicolas Deye, Marc Gainnier, Virginie Siguret, Bruno Mégarbane. Case series of massive direct oral anticoagulant ingestion-Treatment and pharmacokinetics data.
European journal of clinical investigation.
2022 Jun; 52(6):e13746. doi:
10.1111/eci.13746. [PMID: 35000196] - Tatsiana Vaitsiakhovich, Craig I Coleman, Frank Kleinjung, Burcu Vardar, Bernhard Schaefer. Worsening of kidney function in patients with atrial fibrillation and chronic kidney disease: evidence from the real-world CALLIPER study.
Current medical research and opinion.
2022 Jun; 38(6):937-945. doi:
10.1080/03007995.2022.2061705. [PMID: 35392744] - William Towers, Steffany N Nguyen, Melanie C Ruegger, Eric Salazar, Kevin R Donahue. Apixaban and Rivaroxaban Anti-Xa Level Monitoring Versus Standard Monitoring in Hospitalized Patients With Acute Kidney Injury.
The Annals of pharmacotherapy.
2022 06; 56(6):656-663. doi:
10.1177/10600280211046087. [PMID: 34541895] - Min Zhuo, Julie M Paik, Theodore N Tsacogianis, Rishi J Desai. Use of Anticoagulants and Dosing Appropriateness of Apixaban for New-Onset Atrial Fibrillation Among Hemodialysis Patients.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2022 06; 79(6):909-912. doi:
10.1053/j.ajkd.2021.08.014. [PMID: 34571068] - Dan Sly, Margaret Husted, Lynn McKeague, Tamara Everington. 'I just didn't want to trust it at all': Atrial fibrillation patient's treatment experience of rivaroxaban and warfarin.
Journal of evaluation in clinical practice.
2022 06; 28(3):436-444. doi:
10.1111/jep.13628. [PMID: 34636130] - Gabriela Siedler, Kosmas Macha, Svenja Stoll, Johannes Plechschmidt, Ruihao Wang, Stefan T Gerner, Erwin Strasser, Stefan Schwab, Bernd Kallmünzer. Monitoring of direct oral anticoagulants plasma levels for secondary stroke prevention.
Journal of thrombosis and haemostasis : JTH.
2022 05; 20(5):1138-1145. doi:
10.1111/jth.15677. [PMID: 35171533] - Xiaojin Liu, Quan Xiao, Yun Li, Guobing Hu, Wang Kun, Wanbo Xu. Effect of post-discharge pharmacist-led follow-up on drug treatment in patients with deep venous thrombosis in primary hospitals in China.
Pakistan journal of pharmaceutical sciences.
2022 May; 35(3):785-791. doi:
". [PMID: 35791477] - Haithuy Pham, Whitney Gibson Medford, Spencer Horst, Melissa Levesque, David Ragoonanan, Christine Price, Harold Colbassani, Keaton Piper, Keith Chastain. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
The American journal of emergency medicine.
2022 05; 55(?):38-44. doi:
10.1016/j.ajem.2022.02.029. [PMID: 35272069] - Xin Zheng, Chen Chen, Huitao Gao, Xuefeng Sun, Yanbao Zhang, Juhong Shi, Xiaohong Han. Developing LC-MS/MS methods to quantify rivaroxabanin human plasma and urine: Application to therapeutic drug monitoring.
Biomedical chromatography : BMC.
2022 May; 36(5):e5306. doi:
10.1002/bmc.5306. [PMID: 34967030] - Lloyd Wei Tat Tang, Tino Woon Huai Cheong, Eric Chun Yong Chan. Febuxostat and its major acyl glucuronide metabolite are potent inhibitors of organic anion transporter 3: Implications for drug-drug interactions with rivaroxaban.
Biopharmaceutics & drug disposition.
2022 Apr; 43(2):57-65. doi:
10.1002/bdd.2310. [PMID: 35088420] - Giuseppe Di Tano, Meghi Dede, Irene Pellicelli, Enrico Martinelli, Luigi Moschini, Elva Calvaruso, Gian Battista Danzi. Pulmonary embolism in patients with COVID-19 pneumonia on adequate oral anticoagulation.
Journal of thrombosis and thrombolysis.
2022 Apr; 53(3):576-580. doi:
10.1007/s11239-021-02589-y. [PMID: 34708314] - Antonio González Pérez, Yanina Balabanova, María E Sáez, Gunnar Brobert, Luis A García Rodríguez. Renal decline in patients with non-valvular atrial fibrillation treated with rivaroxaban or warfarin: A population-based study from the United Kingdom.
International journal of cardiology.
2022 Apr; 352(?):165-171. doi:
10.1016/j.ijcard.2022.01.063. [PMID: 35122912] - Vladimír Nosáľ, Andrea Petrovičová, Ingrid Škorňová, Tomáš Bolek, Jana Dluhá, Lucia Stančiaková, Štefan Sivák, Lucia Babálová, Gabriel Hajaš, Ján Staško, Peter Kubisz, Egon Kurča, Matej Samoš, Marián Mokáň. Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study.
European journal of clinical pharmacology.
2022 Apr; 78(4):557-564. doi:
10.1007/s00228-022-03280-8. [PMID: 35066599] - Sophie C Dólleman, Stijn M Agten, Henri M H Spronk, Tilman M Hackeng, Mettine H A Bos, Henri H Versteeg, Anton Jan van Zonneveld, Hetty C de Boer. Thrombin in complex with dabigatran can still interact with PAR-1 via exosite-I and instigate loss of vascular integrity.
Journal of thrombosis and haemostasis : JTH.
2022 04; 20(4):996-1007. doi:
10.1111/jth.15642. [PMID: 35037739] - O D Ostroumova, T M Ostroumova, A V Arablinsky, V N Butorova, A I Kochetkova. [Modern issues of improving the prognosis in patients with atrial fibrillation after ischemic stroke].
Kardiologiia.
2022 Mar; 62(3):65-72. doi:
10.18087/cardio.2022.3.n1992. [PMID: 35414363] - Flavio Tarasoutchi, Vitor E E Rosa. Rivaroxaban effects on cardiac valve calcifications, renal preservation and inflammatory modulation: Have we found the panacea?.
International journal of cardiology.
2022 03; 351(?):89-90. doi:
10.1016/j.ijcard.2021.11.063. [PMID: 34861323] - Adane Teshome Kefale, Gregory M Peterson, Woldesellassie M Bezabhe, Luke R Bereznicki. Switching of oral anticoagulants in atrial fibrillation: a cohort study using Australian general practice data.
Expert review of clinical pharmacology.
2022 Mar; 15(3):351-357. doi:
10.1080/17512433.2022.2044793. [PMID: 35184624] - Zachary S Robinson, Katharine L Madding, Dylan Magoto. Delayed Rivaroxaban Elimination in Acute Kidney Injury and Shock Liver.
The Annals of pharmacotherapy.
2022 03; 56(3):366-367. doi:
10.1177/10600280211032293. [PMID: 34259073] - Thom Kok, Hans de Boer, Bart Witteman, Marcel Hovens, Matthijs van Luin, Houshang Monajemi. Anti-Xa Levels in Morbidly Obese Patients Using Apixaban or Rivaroxaban, Before and After Bariatric Surgery.
Obesity surgery.
2022 03; 32(3):607-614. doi:
10.1007/s11695-021-05814-y. [PMID: 34822108] - Steven P Grover, Taylor Coughlin, Salma M Fleifil, Jens J N Posma, Henri H M Spronk, Stefan Heitmeier, A Phillip Owens, Nigel Mackman. Effect of combining aspirin and rivaroxaban on atherosclerosis in mice.
Atherosclerosis.
2022 03; 345(?):7-14. doi:
10.1016/j.atherosclerosis.2022.02.010. [PMID: 35183904] - Sonia Saib, Sophie Hodin, Valérie Bin, Edouard Ollier, Xavier Delavenne. In Vitro Evaluation of P-gp-Mediated Drug-Drug Interactions Using the RPTEC/TERT1 Human Renal Cell Model.
European journal of drug metabolism and pharmacokinetics.
2022 Mar; 47(2):223-233. doi:
10.1007/s13318-021-00744-7. [PMID: 34935100] - Ye Tao, Xin Jiang, Ping Shi, Yanping Liu, Pingping Lin, Shuqin Liu, Ting Li, Yaping Ma, Xiaomeng Gao, Yu Cao. Bioequivalence and Food Effect Assessment of 2 Rivaroxaban Formulations in Healthy Chinese Volunteers: An Open, Randomized, Single-Dose, and 4-Period Crossover Study.
Clinical pharmacology in drug development.
2022 03; 11(3):358-363. doi:
10.1002/cpdd.1031. [PMID: 34637608] - Sarah Hanigan, Jeong M Park. Evaluating pharmacokinetic drug-drug interactions of direct oral anticoagulants in patients with renal dysfunction.
Expert opinion on drug metabolism & toxicology.
2022 Mar; 18(3):189-202. doi:
10.1080/17425255.2022.2074397. [PMID: 35543017] - Maureen A Smythe, Carly Burns, Qianyue Liu, Candice L Garwood. Potential Dexamethasone-Direct Oral Anticoagulant Drug Interaction: Is This a Concern in COVID?.
The Annals of pharmacotherapy.
2022 03; 56(3):319-329. doi:
10.1177/10600280211025042. [PMID: 34137279] - Kunihiko Matsui, Satoshi Yasuda, Koichi Kaikita, Masaharu Akao, Junya Ako, Tetsuya Matoba, Masato Nakamura, Katsumi Miyauchi, Nobuhisa Hagiwara, Kazuo Kimura, Atsushi Hirayama, Hisao Ogawa. The impact of kidney function in patients on antithrombotic therapy: a post hoc subgroup analysis focusing on recurrent bleeding events from the AFIRE trial.
BMC medicine.
2022 02; 20(1):69. doi:
10.1186/s12916-022-02268-6. [PMID: 35209924] - Dhiraj Kumar, Vaishnavi Kaimaparambil, Sheeba Chandralekha, Janvi Lalchandani. Oral Rivaroxaban in the Prophylaxis of COVID-19 Induced Coagulopathy.
The Journal of the Association of Physicians of India.
2022 Feb; 70(2):11-12. doi:
NULL. [PMID: 35436816] - Ray J Li, Gillian E Caughey, Sepehr Shakib. Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation.
Journal of thrombosis and thrombolysis.
2022 Feb; 53(2):425-435. doi:
10.1007/s11239-021-02528-x. [PMID: 34302286] - T S Shahzada, C L Guo, A P W Lee. Renal outcomes in Asian patients receiving oral anticoagulants for non-valvular atrial fibrillation.
Hong Kong medical journal = Xianggang yi xue za zhi.
2022 Feb; 28(1):24-32. doi:
10.12809/hkmj209201. [PMID: 34737236] - Izabela Zakrocka, Wojciech Załuska. Anticoagulant-related nephropathy: Focus on novel agents. A review.
Advances in clinical and experimental medicine : official organ Wroclaw Medical University.
2022 Feb; 31(2):165-173. doi:
10.17219/acem/142657. [PMID: 35212199] - Christian Pfrepper, Lisa-Charlott Behrendt, Hagen Bönigk, Thomas Siegemund, Michael Metze, Dirk Franke, Sirak Petros, Annelie Siegemund. Influence of direct oral anticoagulants on thrombin generation on Ceveron TGA.
International journal of laboratory hematology.
2022 Feb; 44(1):193-201. doi:
10.1111/ijlh.13721. [PMID: 34585540] - Henrik von Horn, Agnes Rasmusson, Lisbeth Söderblom, Rickard E Malmström, Jovan Antovic. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
International journal of laboratory hematology.
2022 Feb; 44(1):163-167. doi:
10.1111/ijlh.13692. [PMID: 34523813] - Nicola Potere, Matteo Candeloro, Ettore Porreca, Stefano Marinari, Camilla Federici, Raffaella Auciello, Marcello Di Nisio. Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone.
Journal of thrombosis and thrombolysis.
2022 Feb; 53(2):346-351. doi:
10.1007/s11239-021-02561-w. [PMID: 34498156] - A Ya Kovaleva, V L Lukinov, G I Lifshits. [Atrial fibrillation and cognitive impairment: features of the relationship, developmental and prevention mechanisms].
Kardiologiia.
2022 Jan; 62(1):80-88. doi:
10.18087/cardio.2022.1.n1904. [PMID: 35168537] - Tuba Reçber, İbrahim Celalettin Haznedaroğlu, Mustafa Çelebier. Review on Characteristics and Analytical Methods of Rivaroxaban.
Critical reviews in analytical chemistry.
2022; 52(4):865-877. doi:
10.1080/10408347.2020.1839735. [PMID: 33146024] - Eduardo Ramacciotti, Leandro Barile Agati, Daniela Calderaro, Valéria Cristina Resende Aguiar, Alex C Spyropoulos, Caroline Candida Carvalho de Oliveira, Jessica Lins Dos Santos, Giuliano Giova Volpiani, Marcone Lima Sobreira, Edwaldo Edner Joviliano, Milton Sérgio Bohatch Júnior, Benedito Antônio Lopes da Fonseca, Maurício Serra Ribeiro, Cesar Dusilek, Kengi Itinose, Suzanna Maria Viana Sanches, Karine de Almeida Araujo Ramos, Nara Franzin de Moraes, Paulo Fernando Guimarães Morando Marzocchi Tierno, André Luiz Malavasi Longo de Oliveira, Adriano Tachibana, Rodrigo Caruso Chate, Marcus Vinícius Barbosa Santos, Bruno Bezerra de Menezes Cavalcante, Ricardo Cesar Rocha Moreira, Chiann Chang, Alfonso Tafur, Jawed Fareed, Renato D Lopes. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.
Lancet (London, England).
2022 01; 399(10319):50-59. doi:
10.1016/s0140-6736(21)02392-8. [PMID: 34921756] - Myrthe M A Toorop, Nienke van Rein, Melchior C Nierman, Helga W Vermaas, Menno V Huisman, Felix J M van der Meer, Suzanne C Cannegieter, Willem M Lijfering. Inter- and intra-individual concentrations of direct oral anticoagulants: The KIDOAC study.
Journal of thrombosis and haemostasis : JTH.
2022 01; 20(1):92-103. doi:
10.1111/jth.15563. [PMID: 34664401] - Mindi Zhao, Xiaoyan Liu, Xiaoxiao Bu, Yao Li, Meng Wang, Bo Zhang, Wei Sun, Chuanbao Li. Application of plasma metabolome for monitoring the effect of rivaroxaban in patients with nonvalvular atrial fibrillation.
PeerJ.
2022; 10(?):e13853. doi:
10.7717/peerj.13853. [PMID: 35966924] - Songsong Lu, Nurzat Huerman, Meng Li, Qingming Ding, Ying Song, Qinzhu Xu, Jiang Rong, Jian Xu, Chen Liu. Evaluation of Activated Carbon Treatment on Overcoming the Interference of Rivaroxaban on the Detection of Functional Lupus Anticoagulant.
Acta haematologica.
2022; 145(4):430-439. doi:
10.1159/000522324. [PMID: 35100578] - Katarzyna Papaj, Patrycja Spychalska, Patryk Kapica, André Fischer, Jakub Nowak, Maria Bzówka, Manuel Sellner, Markus A Lill, Martin Smieško, Artur Góra. Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease.
PloS one.
2022; 17(1):e0262482. doi:
10.1371/journal.pone.0262482. [PMID: 35015795] - Yongyong Dong, Guangbin Duan, Huihui Wang, Jia Ru, Yong Cui. A Cohort Study of Rivaroxaban Combined with D-Dimer Dynamic Monitoring in the Prevention of Deep Venous Thrombosis after Knee Arthroplasty.
Computational and mathematical methods in medicine.
2022; 2022(?):3965039. doi:
10.1155/2022/3965039. [PMID: 35495880] - Fang Ma, Li Yuan, Xinli Wen, Yangyang Wang, Qiaofei Li, Chu Chen. Efficacy and Safety of Direct Oral Anticoagulants in Stable Coronary Artery Disease and Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
2022 Jan; 28(?):10760296221131033. doi:
10.1177/10760296221131033. [PMID: 36198012] - Luca Di Lullo, Carlo Lavalle, Michele Magnocavallo, Marco Valerio Mariani, Domenico Giovanni Della Rocca, Paolo Severino, Biagio Raffaele Di Iorio, Domenico Russo, Francesco Summaria, Giovanni Battista Forleo, Claudio Ronco, Massimo Mancone, Cristina Chimenti, Fabio Miraldi, Andrea Natale, Antonio Bellasi. New evidence of direct oral anticoagulation therapy on cardiac valve calcifications, renal preservation and inflammatory modulation.
International journal of cardiology.
2021 Dec; 345(?):90-97. doi:
10.1016/j.ijcard.2021.10.025. [PMID: 34688719] - Shin-Yi Lin, Ching-Hua Kuo, Tao-Min Huang, Yu-Fong Peng, Chih-Fen Huang, Sung-Chun Tang, Jiann-Shing Jeng. Impact of different renal function equations on direct oral anticoagulant concentrations.
Scientific reports.
2021 12; 11(1):23833. doi:
10.1038/s41598-021-03318-4. [PMID: 34903821] - Andrea Rubboli, Claudio Fresco, Maurizio Paciaroni, Bianca Rocca, Domenico Pecora, Iolanda Enea, Claudio Cuccia, Giuseppe Patti. How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group.
Journal of cardiovascular medicine (Hagerstown, Md.).
2021 Dec; 22(11):924-928. doi:
10.2459/jcm.0000000000001204. [PMID: 33927142] - Emmanouela Kampouraki, Peter Avery, Tina Biss, Hilary Wynne, Farhad Kamali. Assessment of exposure to direct oral anticoagulants in elderly hospitalised patients.
British journal of haematology.
2021 12; 195(5):790-801. doi:
10.1111/bjh.17899. [PMID: 34658009] - Frank Pistrosch, Jan B Matschke, Dorothea Schipp, Bernhard Schipp, Elena Henkel, Ingo Weigmann, Jan Sradnick, Stefan R Bornstein, Andreas L Birkenfeld, Markolf Hanefeld. Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers.
Diabetologia.
2021 12; 64(12):2701-2712. doi:
10.1007/s00125-021-05562-9. [PMID: 34495376] - Kathrine Parker, Janette Chu, Muir Morton, Shiv Bhutani, Michael Picton, Sandip Mitra, Jecko Thachil. Can direct oral anticoagulants be used in kidney transplant recipients?.
Clinical transplantation.
2021 12; 35(12):e14474. doi:
10.1111/ctr.14474. [PMID: 34498777] - Eduardo Ramacciotti, Leandro Barile Agati, Daniela Calderaro, Giuliano Giova Volpiani, Caroline Candida Carvalho de Oliveira, Valéria Cristina Resende Aguiar, Elizabeth Rodrigues, Marcone Lima Sobreira, Edwaldo Edner Joviliano, Cesar Dusilek, Kenji Itinose, Rogério Aparecido Dedivitis, André Sementilli Cortina, Suzanna Maria Viana Sanches, Nara Franzin de Moraes, Paulo Fernando Guimarães Morando Marzocchi Tierno, André Luiz Malavasi Longo de Oliveira, Adriano Tachibana, Rodrigo Caruso Chate, Marcus Vinícius Barbosa Santos, Bruno Bezerra de Menezes Cavalcante, Ricardo Cesar Rocha Moreira, Chang Chiann, Alfonso Tafur, Alex C Spyropoulos, Renato D Lopes. Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial.
American heart journal.
2021 12; 242(?):115-122. doi:
10.1016/j.ahj.2021.08.016. [PMID: 34480880] - Hakeam A Hakeam, Mohammed Alkhani, Zyad Alyahya, Ziyad Alawaji, Sandra Ofori. Direct Acting Oral Anticoagulants Following Gastrointestinal Tract Surgery.
Journal of cardiovascular pharmacology.
2021 12; 78(6):867-874. doi:
10.1097/fjc.0000000000001142. [PMID: 34882113] - Zhiyan Liu, Qiufen Xie, Hanxu Zhang, Guangyan Mu, Shuang Zhou, Zining Wang, Jie Jiang, Qian Xiang, Yimin Cui. Target Drug-Calibrated Anti-Xa Activity Assays and Expected Peak-Trough Levels in an Asian Population: A Multicenter Study.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
2021 Nov; 21(6):669-679. doi:
10.1007/s40256-021-00479-5. [PMID: 34142346] - Agnieszka Kotalczyk, Srinivasa Rao Vallabhaneni, Gregory Y H Lip. Review new concepts in pharmacotherapy for peripheral arterial disease.
Current opinion in cardiology.
2021 11; 36(6):720-726. doi:
10.1097/hco.0000000000000883. [PMID: 34620790] - Masato Narita, Kenji Hanada, Yosuke Kawamura, Hiroaki Ichikawa, Shuntaro Sakai, Yoshikazu Yokono, Maiko Senoo, Noritomo Narita, Michiko Shimada, Tomohiro Osanai, Ken Okumura, Hirofumi Tomita. Rivaroxaban attenuates cardiac hypertrophy by inhibiting protease-activated receptor-2 signaling in renin-overexpressing hypertensive mice.
Hypertension research : official journal of the Japanese Society of Hypertension.
2021 10; 44(10):1261-1273. doi:
10.1038/s41440-021-00700-7. [PMID: 34285375] - Katharina Thuile, Katia Giacomuzzi, Erika Jani, Peter Marschang, Thomas Mueller. Evaluation of the in vitro stability of direct oral anticoagulants in blood samples under different storage conditions.
Scandinavian journal of clinical and laboratory investigation.
2021 Oct; 81(6):461-468. doi:
10.1080/00365513.2021.1946844. [PMID: 34278897] - Lei Xiao, Xiaoying Zheng, Huiming Jiang, Wei Huang, Feng Qiu, Xinyu Li. Risk factors for ecchymosis in patients receiving rivaroxaban for thromboprophylaxis after total knee arthroplasty: a retrospective cohort study.
Journal of clinical pharmacy and therapeutics.
2021 Oct; 46(5):1281-1287. doi:
10.1111/jcpt.13420. [PMID: 33768580] - Thibaud Cavaillez, Laurent Weinmann, Christine Mouton, Céline Delassasseigne, Musa Sesay, Matthieu Biais, Chloé James, Stéphanie Roullet. A retrospective study of indications and consequences of monitoring direct oral anticoagulant plasma concentrations on patient care in a university hospital: The Retro-AOD study.
Thrombosis research.
2021 Oct; 206(?):76-83. doi:
10.1016/j.thromres.2021.08.010. [PMID: 34419866] - Ziv Harel, Eric McArthur, Nivethika Jeyakumar, Manish M Sood, Amit X Garg, Samuel A Silver, Paul Dorian, Daniel Blum, William Beaubien-Souligny, Andrew T Yan, Sunil V Badve, Brendan Smyth, Min Jun, Racquel Jandoc, Abhijat Kitchlu, Ron Wald. The Risk of Acute Kidney Injury with Oral Anticoagulants in Elderly Adults with Atrial Fibrillation.
Clinical journal of the American Society of Nephrology : CJASN.
2021 10; 16(10):1470-1479. doi:
10.2215/cjn.05920421. [PMID: 34407990] - Luisa Weiss, John Keaney, Paulina B Szklanna, Tadhg Prendiville, Wido Uhrig, Kieran Wynne, Sarah Kelliher, Karl Ewins, Shane P Comer, Karl Egan, Ellen O'Rourke, Eric Moran, Georgi Petrov, Ashish Patel, Áine Lennon, Alfonso Blanco, Barry Kevane, Sean Murphy, Fionnuala Ní Áinle, Patricia B Maguire. Nonvalvular atrial fibrillation patients anticoagulated with rivaroxaban compared with warfarin exhibit reduced circulating extracellular vesicles with attenuated pro-inflammatory protein signatures.
Journal of thrombosis and haemostasis : JTH.
2021 10; 19(10):2583-2595. doi:
10.1111/jth.15434. [PMID: 34161660] - Aileen C Scheibner, Crystal Franco-Martinez, Elisabeth Kincaide, Reed Hall, Christina Long. The Impact of Rivaroxaban and Apixaban on Tacrolimus Trough Levels.
Progress in transplantation (Aliso Viejo, Calif.).
2021 09; 31(3):236-241. doi:
10.1177/15269248211024601. [PMID: 34155947] - Olivia S Costa, Bridget O'Donnell, Burcu Vardar, Khaled Abdelgawwad, Christopher W Brescia, Nitesh Sood, Craig I Coleman. Kidney, limb and ophthalmic complications, and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: an electronic health record analysis.
Current medical research and opinion.
2021 09; 37(9):1493-1500. doi:
10.1080/03007995.2021.1947217. [PMID: 34166150] - Hafez M Abdullah, Waqas Ullah, Munnam Sohail Jafar, Martin van Zyl, Rehan Saeed, Mahboob Alam, M Chadi Alraies, David L Fischman. Safety and Efficacy of Apixaban, Rivaroxaban, and Warfarin in End-Stage Renal Disease With Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Cardiovascular revascularization medicine : including molecular interventions.
2021 09; 30(?):26-32. doi:
10.1016/j.carrev.2020.09.041. [PMID: 34420589] - Vincenzo Russo, Dario Cattaneo, Laura Giannetti, Roberta Bottino, Nunzia Laezza, Umberto Atripaldi, Emilio Clementi. Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity.
Clinical therapeutics.
2021 09; 43(9):e255-e263. doi:
10.1016/j.clinthera.2021.07.003. [PMID: 34366151] - Hirotsugu Atarashi, Shinichiro Uchiyama, Hiroshi Inoue, Takanari Kitazono, Takeshi Yamashita, Wataru Shimizu, Takanori Ikeda, Masahiro Kamouchi, Koichi Kaikita, Koji Fukuda, Hideki Origasa, Hiroaki Shimokawa. Ischemic stroke, hemorrhage, and mortality in patients with non-valvular atrial fibrillation and renal dysfunction treated with rivaroxaban: sub-analysis of the EXPAND study.
Heart and vessels.
2021 Sep; 36(9):1410-1420. doi:
10.1007/s00380-021-01810-5. [PMID: 33728513] - Alethea Charlton, Xavier Vidal, Mònica Sabaté, Elena Bailarín, Lina María Leguízamo Martínez, Luisa Ibáñez. Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation.
Journal of managed care & specialty pharmacy.
2021 Sep; 27(9):1210-1220. doi:
10.18553/jmcp.2021.27.9.1210. [PMID: 34464214] - Alexandre Cavenatti de Oliveira, Marcelo Gomes Davanço, Daniel Rossi de Campos, Pedro Henrique Godoy Sanches, João Pedro Gonçalves Cirino, Patricia de Oliveira Carvalho, Márcia Aparecida Antônio, Edvaldo Capobiango Coelho, Andreia M Porcari. Sensitive LC-MS/MS method for quantification of rivaroxaban in plasma: Application to pharmacokinetic studies.
Biomedical chromatography : BMC.
2021 Sep; 35(9):e5147. doi:
10.1002/bmc.5147. [PMID: 33885176] - Matthias Karer, Karin Stiasny, Markus Zeitlinger, Bernd Jilma. Subcutaneous injection of mRNA vaccines against severe acute respiratory syndrome coronavirus 2: an option for severe bleeding disorders or anticoagulated patients?.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
2021 09; 32(6):423-424. doi:
10.1097/mbc.0000000000001048. [PMID: 34397451] - Eric Rytkin, Irina V Bure, Pavel O Bochkov, Kristina A Akmalova, Karin B Mirzaev, Marina S Cherniaeva, Olga D Ostroumova, Valery V Smirnov, Elena A Grishina, Anna G Saribekian, Igor N Sychev, Dmitry A Sychev. MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring.
Drug metabolism and personalized therapy.
2021 08; 37(1):41-46. doi:
10.1515/dmpt-2021-0118. [PMID: 35385896] - Gregory Y H Lip, Allison V Keshishian, Yan Zhang, Amiee Kang, Amol D Dhamane, Xuemei Luo, Christian Klem, Mauricio Ferri, Jenny Jiang, Huseyin Yuce, Steven Deitelzweig. Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding.
JAMA network open.
2021 08; 4(8):e2120064. doi:
10.1001/jamanetworkopen.2021.20064. [PMID: 34398204] - Geoffrey Foulon-Pinto, Georges Jourdi, Julien Perrin, Johan Abdoul, Guillaume Paris, Isabelle Gouin-Thibault, Emmanuel Curis, Thomas Lecompte, Virginie Siguret. Study of thrombin generation with St Genesia to evaluate xaban pharmacodynamics: Analytical performances over 18 months.
International journal of laboratory hematology.
2021 Aug; 43(4):821-830. doi:
10.1111/ijlh.13443. [PMID: 33369212] - Matthieu Bourdin, Delphine Perrotin, Olivier Mathieu, Tristan Herve, François Depasse, Genmin Lu, Pamela B Conley, Geneviève Contant. Measuring residual anti-Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa.
International journal of laboratory hematology.
2021 Aug; 43(4):795-801. doi:
10.1111/ijlh.13591. [PMID: 34092030] - Veronica Ashton, Sylvia Kerolus-Georgi, Kenneth T Moore. The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations.
Journal of clinical pharmacology.
2021 08; 61(8):1010-1026. doi:
10.1002/jcph.1838. [PMID: 33599985] - Shigeto Horita, Takeshi Zoshima, Satoshi Hara, Makoto Koichi, Sun Hirayama, Kazuyuki Suzuki, Akikatsu Nakashima, Mitsuhiro Kawano. Antiphospholipid antibody syndrome-associated renal thrombotic microangiopathy improved not with rivaroxaban but with warfarin in a systemic lupus erythematosus patient without lupus nephritis.
CEN case reports.
2021 08; 10(3):409-413. doi:
10.1007/s13730-021-00581-2. [PMID: 33595828] - Renato D Lopes, Pedro Gabriel Melo de Barros E Silva, Remo H M Furtado, Ariane Vieira Scarlatelli Macedo, Eduardo Ramacciotti, Lucas Petri Damini, Bruna Bronhara, Alexandre B Cavalcanti, Regis G Rosa, Luciano C P Azevedo, Viviane C Veiga, Flávia R Machado, Luiz Eduardo Ritt, Priscilla de Aquino Martins, John H Alexander, Alvaro Avezum, Otavio Berwanger. Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial.
American heart journal.
2021 08; 238(?):1-11. doi:
10.1016/j.ahj.2021.04.005. [PMID: 33891907] - John W Eikelboom, Deepak L Bhatt, Keith A A Fox, Jacqueline Bosch, Stuart J Connolly, Sonia S Anand, Alvaro Avezum, Scott D Berkowitz, Kelley R H Branch, Gilles R Dagenais, Camilo Félix, Tomasz J Guzik, Robert G Hart, Aldo P Maggioni, Eva Muehlhofer, Mukul Sharma, Olga Shestakovska, Salim Yusuf. Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease.
Journal of the American College of Cardiology.
2021 07; 78(1):14-23. doi:
10.1016/j.jacc.2021.04.083. [PMID: 34210409] - Yuqiao Chen, Xiu Feng, Chenliang Qi, Lingfeng Zhou, Yi Sun, Zhenhua Gu, Xiaolong Li. Efficacy and safety of Xa inhibitors in patients with heart failure and coronary or peripheral artery disease: a systematic review and meta-analysis of randomized controlled trials.
Annals of palliative medicine.
2021 Jul; 10(7):8082-8093. doi:
10.21037/apm-21-1645. [PMID: 34353093] - Satoru Mitsuboshi, Takahiro Niimura, Yoshito Zamami, Keisuke Ishizawa. Differences in risk factors for anticoagulant-related nephropathy between warfarin and direct oral anticoagulants: Analysis of the Japanese adverse drug event report database.
British journal of clinical pharmacology.
2021 07; 87(7):2977-2981. doi:
10.1111/bcp.14688. [PMID: 33270271] - Ingrid Škorňová, Matej Samoš, Tomáš Bolek, Alena Kamenišťáková, Lucia Stančiaková, Peter Galajda, Ján Staško, Peter Kubisz, Marián Mokáň. Direct Oral Anticoagulants Plasma Levels in Patients with Atrial Fibrillation at the Time of Bleeding: A Pilot Prospective Study.
Journal of cardiovascular pharmacology.
2021 07; 78(1):e122-e127. doi:
10.1097/fjc.0000000000001038. [PMID: 34173805] - Emmanouela Kampouraki, Salah Abohelaika, Peter Avery, Tina Biss, Paul Murphy, Hilary Wynne, Farhad Kamali. Elderly people are inherently sensitive to the pharmacological activity of rivaroxaban: implications for DOAC prescribing.
Journal of thrombosis and thrombolysis.
2021 Jul; 52(1):170-178. doi:
10.1007/s11239-020-02326-x. [PMID: 33131001] - Akira Sezai, Makoto Taoka, Shunji Osaka, Yoshiki Kitazumi, Keito Suzuki, Keita Kamata, Masashi Tanaka. A Comparative Prospective Observational Study on the Use of Direct Oral Anticoagulants after Cardiac Surgery for the Management of Atrial Fibrillation.
Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.
2021 Jun; 27(3):191-199. doi:
10.5761/atcs.oa.20-00213. [PMID: 33208579] - Renato D Lopes, Pedro Gabriel Melo de Barros E Silva, Remo H M Furtado, Ariane Vieira Scarlatelli Macedo, Bruna Bronhara, Lucas Petri Damiani, Lilian Mazza Barbosa, Júlia de Aveiro Morata, Eduardo Ramacciotti, Priscilla de Aquino Martins, Aryadne Lyrio de Oliveira, Vinicius Santana Nunes, Luiz Eduardo Fonteles Ritt, Ana Thereza Rocha, Lucas Tramujas, Sueli V Santos, Dario Rafael Abregu Diaz, Lorena Souza Viana, Lívia Maria Garcia Melro, Mariana Silveira de Alcântara Chaud, Estêvão Lanna Figueiredo, Fernando Carvalho Neuenschwander, Marianna Deway Andrade Dracoulakis, Rodolfo Godinho Souza Dourado Lima, Vicente Cés de Souza Dantas, Anne Cristine Silva Fernandes, Otávio Celso Eluf Gebara, Mauro Esteves Hernandes, Diego Aparecido Rios Queiroz, Viviane C Veiga, Manoel Fernandes Canesin, Leonardo Meira de Faria, Gilson Soares Feitosa-Filho, Marcelo Basso Gazzana, Idelzuíta Leandro Liporace, Aline de Oliveira Twardowsky, Lilia Nigro Maia, Flávia Ribeiro Machado, Alexandre de Matos Soeiro, Germano Emílio Conceição-Souza, Luciana Armaganijan, Patrícia O Guimarães, Regis G Rosa, Luciano C P Azevedo, John H Alexander, Alvaro Avezum, Alexandre B Cavalcanti, Otavio Berwanger. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.
Lancet (London, England).
2021 06; 397(10291):2253-2263. doi:
10.1016/s0140-6736(21)01203-4. [PMID: 34097856] - Kaisei Kamatani, Tsuneaki Kenzaka, Ryu Sugimoto, Ayako Kumabe, Akihito Kitao, Hozuka Akita. Multiple thrombosis associated with Cytomegalovirus enterocolitis in an immunocompetent patient: a case report.
BMC infectious diseases.
2021 Jun; 21(1):530. doi:
10.1186/s12879-021-06230-4. [PMID: 34090366] - Gabriello Marchetti, Francesco Bernardini, Michele Romoli, Stefano Urbinati. Switching across direct oral anticoagulants: a real-life-setting pilot prospective study.
Journal of cardiovascular medicine (Hagerstown, Md.).
2021 06; 22(6):453-458. doi:
10.2459/jcm.0000000000001118. [PMID: 33186238] - Lin Liu, Dongsheng Hong, Kuifen Ma, Xiaoyang Lu. Cost-effectiveness of rivaroxaban versus warfarin in non-valvular atrial fibrillation patients with chronic kidney disease in China.
Journal of clinical pharmacy and therapeutics.
2021 Jun; 46(3):658-668. doi:
10.1111/jcpt.13318. [PMID: 33226144] - Catherine Y S Cheung, Jash Parikh, Ashley Farrell, Melissa Lefebvre, Claudia Summa-Sorgini, Marisa Battistella. Direct Oral Anticoagulant Use in Chronic Kidney Disease and Dialysis Patients With Venous Thromboembolism: A Systematic Review of Thrombosis and Bleeding Outcomes.
The Annals of pharmacotherapy.
2021 06; 55(6):711-722. doi:
10.1177/1060028020967635. [PMID: 33073581] - Muzaffar Iqbal, Zabih Ullah, Essam Ezzeldin, Nasr Y Khalil, Nasser S Al-Shakliah, Abdulrahman Alrasheed, Ishtiaque Ahmad, Luluh Albehlal. A simple and sensitive HILIC-based UHPLC-MS/MS method for quantifying of rivaroxaban in dried blood spots: Application in comparison with the plasma sample method.
Journal of pharmaceutical and biomedical analysis.
2021 May; 198(?):114023. doi:
10.1016/j.jpba.2021.114023. [PMID: 33744464] - Matthias Klages, Florian J Raimann, Anna-Lena Philipp, Edelgard Lindhoff-Last, Kai Zacharowski, Haitham Mutlak. Direct oral anticoagulants in point-of-care monitoring: an ex-vivo study.
Minerva anestesiologica.
2021 05; 87(5):514-522. doi:
10.23736/s0375-9393.21.14788-1. [PMID: 33591135] - Jameel Abdulrehman, Rita Selby, Raed A Joundi, Erik Yeo. Peak plasma rivaroxaban levels in patients weighing 120 kg or greater.
Thrombosis research.
2021 05; 201(?):15-17. doi:
10.1016/j.thromres.2021.02.013. [PMID: 33626462]